Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Myelogenous Leukemia: early-phase trial registry
10 of 30 indexed Chronic Myelogenous Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 10 currently recruiting · #519 of 28,707 conditions by registered trial count
Chronic Myelogenous Leukemia: 30 US clinical trials tracked, 10 recruiting.
Chronic Myelogenous Leukemia is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 4 of these trials.
Enrollment posture brief
Registry condition chronic-myelogenous-leukemia
OPEN 10 | RECR 33% | LATE 2 | EARLY 23 | RANK #519 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Chronic Myelogenous Leukemia lists 10 open slots (33% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Myelogenous Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Myelogenous Leukemia is recruiting below its size-band peers.
10 of 30 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Myelogenous Leukemia trials is spread across many organizations.
Masonic Cancer Center, University of Minnesota accounts for 4 of 30 trials (13.3%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Myelogenous Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 30 trials that report a genuine target (sentinel values excluded). 19 of those (63.3%) plan for fewer than 100 participants.
-
Chronic Myelogenous Leukemia research is mostly interventional.
26 interventional and 4 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
M.D. Anderson Cancer Center
NCT00816114
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
Asciminib Roll-over Study
Novartis Pharmaceuticals
NCT04877522
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01962636
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Shenzhen TargetRx Co.
NCT06088888
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT05088356
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05805605
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Leland Metheny
NCT06680661
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04904588
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03674411
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT01494103
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Novartis Pharmaceuticals
NCT00109707
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT02208037
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Novartis Pharmaceuticals
NCT01784068
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Heart, Lung, and Blood Institute (NHLBI)
NCT00003838
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Notable Labs
NCT04014764
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Novartis Pharmaceuticals
NCT00980018
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie (prior sponsor, Abbott)
NCT01110473
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT00674479
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Baylor College of Medicine
NCT00368355
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01517035
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals
NCT00041990
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
ViaCell
NCT00089596
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
Bayer
NCT00661180
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
NCT01390402
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Myelogenous Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Myelogenous Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Myelogenous Leukemia page
30 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Chronic Myelogenous Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Masonic Cancer Center, University of Minnesota sponsors the most Chronic Myelogenous Leukemia trials on record, review their full trial history before evaluating a specific study. See Masonic Cancer Center, University of Minnesota's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Myelogenous Leukemia condition card totals 30 registered trials; most-linked intervention Fludarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.